Trial | NCT00409201  Report issue

Title

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    reboxetine ...

  • Study Participants

    30
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
all participants will be administered panss, sans, esrs, calgary, progesterom, sexual functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on the first visit, as well as blood tests, ecg and weight. they will then be tested using a computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given either a two week dose of placebo or treatment (2 mg * 2 daily for first week, then 4 mg. day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. * 2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is concluded at 6 weeks, following a readministration of tests. physical examination is also administered at the conclusion.
Study Started
Mar 31
2006
Study Completion
Nov 30
2006
Last Update
Dec 08
2006
Estimate

Drug reboxetine adjuvant therapy

Criteria 

Inclusion Criteria:

schizophrenia all types
18>

Exclusion Criteria:

uti
>65
non organic state
no depression treatment
No Results Posted